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INTRODUCTION
In the last decade there has been increasing prevalence of
infections caused by multidrug-resistant organisms
(MDRO), including by multidrug-resistant Acinetobacter
baumannii. MDRAB is among the most difficult anti-
microbial-resistant gram-negative bacilli to manage. Most
common healthcare-associated infections caused by
MDRAB are nosocomial pneumonia (especially ventilation
pneumonia), central venous catheter infections, urinary tract
infections, surgical site infections, skin and soft tissue infec-
tions and meningitis (Maragakis and Perl, 2008). Bacterae-
mia often develops leading to invasive infection (when bac-
teria are isolated from blood and/or cerebrospinal liquor)
with a bad prognosis.
Bacteremia is a very common complication, especially in
ICU due to catheter colonisation. Usually it develops on av-
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There has been an increasing tendency of infections caused by multidrug-resistant organisms
(MDRO), including multidrug-resistant Acinetobacter baumannii (MDRAB), in the Rîga East Uni-
versity Hospital (REUH) during the last decade. Over the last two years (2014–2015), this ten-
dency has reversed and the prevalence of MDRAB has decreased considerably. In this study we
assessed the prevalence of MDRAB in intensive care units (ICUs), internal medicine, surgery
units and analysed antibiotic sensitivity profiles. In addition, we determined if current infection
control measures are preventing further increase of infections caused by MDRAB in REUH.
Retrospective Acinetobacter baumannii prevalence data were collected for the period from 2009
until 2012. For the time period from the beginning of 2013 until 2015, after implementing such in-
fection control measures as control of compliance to hand hygiene guidelines, a review of central
venous catheter insertion protocols and regular search for sources of MDRAB in hospital environ-
ment, prospective follow-up of new cases was conducted. Antimicrobial sensitivity profiles were
assessed for the period from 2013 until 2015. Data were processed with the statistical software
WHONET 5.5. Bacteria identification and antibiotic susceptibility testing were performed by
VITEK 2 compact, BioMerieux, France. The prevalence of MDRAB in the period 2009 to 2013 in-
creased from 71 to 217 cases per year, but from between 2013 (time of implementing infection
control measures) and 2015 it decreased to 113 cases in 2015. In the three year period
(2013–2015), the proportion of MDRAB causing bloodstream infections (BSI) and central nervous
system infections (CNSI) was 15.85% from all identified MDRAB cases. Of the 113 MDRAB infec-
tions diagnosed in 2015, BSI was found in 16.81% cases (n = 19). Antibiotic resistance testing
showed that colistin is the most effective drug against MDRAB. The majority of Acinetobacter
baumannii isolates were resistant to Ampicillin/Sulbactam, Piperacillin/Tazobactam, Ceftazidime,
Cefepime, Imipenem, Meropenem, Amikacin, Gentamicin, Tobramycin, and Ciprofloxacin. Over
the last two years (2014–2015), prevalence of MDRAB infections decreased considerably. In the
time period from 2013 to 2014, resistance of Acinetobacter baumannii increased to imipenem,
ciprofloxacin and colistin, while decreased slightly to amikacin. Rigorous infection control mea-
sures, such as identification and elimination of new MDRAB sources in environment, review of the
central venous catheter insertion protocol and improvements in hand hygiene, are crucial for de-
creasing distribution of and invasive infections caused by MDRAB in the hospital environment.
Key words: multidrug-resistant Acinetobacter baumannii (MDRAB), infection control, resistance,
bloodstream infections, colistin.
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erage 26 days after admission (Peleg et al., 2008). De-
pending on the source, Acinetobacter baumannii accounts
for about 1.5 to 2.4% of healthcare associated bloodstream
infections. In France, Acinetobacter baumannii accounted
for 12% of bloodstream infections (Fournier and Richet,
2006). Over 90% of infections with Acinetobacter
baumannii are recognised to be hospital-acquired, while
only 4% are community-acquired, mostly pneumonia cases.
In general, Acinetobacter baumannii accounts for a mortal-
ity rate in ICU of about 60%. There are few studies that pro-
vide exact numbers of infected persons, as it is very difficult
to discern true infection from only colonization. The biggest
problem is, when MDRAB is recognized, how to treat it?
In 2014, WHO released a publication on the threat of in-
creasing antimicrobial resistance (Anonymous, 2014b). The
main focus was on carbapenems, as this antimicrobial agent
is mostly used as last resort for treating many infections. In
2009, European surveillance data showed that 17% of bac-
teremia infections in ICU and almost 12% of UTI infections
in ICU were caused by Acinetobacter spp.
Highest data was seen in Italy, Lithuania, and Slovakia.
Survey has been conducted in several countries of resistant
strains of Acinetobacter baumannii isolates, and up to 80%
of strains have proven to have carbapenem resistance and
47% imipenem resistance. US-wide surveillance data
showed that prevalence of carbapenem-resistant strains has
increased from 5.2% in 1999 to 40.8% in 2010.
Acinetobacter baumannii (genospecies 2 of the ACB com-
plex — A. calcoaceticus–A. baumannii) is the most resistant
strain of Acinetobacter spp. It harbours various genes,
which makes it resistant to multiple antimicrobial agents,
the most common being: beta-lactamase genes (genes cod-
ing for aminoglycoside-modifying enzymes), disinfectant-
sulfanilamide resistance (qacEDelta1-sul1) genes, class 1
integrase (intl1) gene, the qnr gene associated with plasmid-
mediated quinolone resistance, and OXA-type genes for
carbapenem-resistance (type 51 (Europe), and 23 and 58
(USA) being the most common ones) (Anonymous, 2014b).
Septic shock develops in up to one-third of patients with
bacteraemia. There is a trend of increasing MDRAB resis-
tance to various widely used antibiotics and sometimes few
options are available for saving a patient’s life. Timely im-
plementation of infection control measures, such as hand
hygiene (Gould et al., 2010), control of central venous
catheter insertion protocols (Bishop et al., 2007; Anony-
mous, 2012b) and hospital environmental MDRAB infec-
tion control (Anonymous, 2003; Obeidat et al., 2014) are
extremely important to decrease spread of MDRO including
MDRAB in the hospital environment and also decrease car-
riage of MDRO in out-patient setting.
MATERIALS AND METHODS
Rîga East University Hospital is one of the biggest health
care institutions in Latvia, comprising 2120 beds, including
78 beds in Intensive Care Units (ICU). In 2014, the hospital
provided health care services to 72 404 in-patients and
320 700 out-patients, including patients in ICU. There were
28 418 surgeries performed in 2014. A retrospective study
was conducted of patients admitted to Rîga East University
Hospital (REUH) from 2009 until 2012 and prospective
follow-up of new cases after implementing of infection con-
trol measures since the beginning of 2013. The following
infection control measures have been implemented: review
of all protocols that guide insertion of invasive devices in-
cluding central venous catheter, identifying sources of
MDRAB in the hospital (ventilation systems, ventilators of
computers), and control of hand hygiene in all departments
of the hospital.
Data were collected based on clinical situations, and cul-
tures were taken from blood, cerebrospinal fluid, bronchial
specimens and swabs from wounds.
Bacteria identification and antibiotic susceptibility testing
were performed using a VITEK 2 compact, BioMerieux,
France.
Acinetobacter baumannii isolates were tested for sensitivity
to ampicillin-sulbactam (SAM), piperacillin-tazobactam
(TZP), ceftazidime (CAZ), cefepime (FEP), imipenem
(IPM), meropenem (MEM), amikacin (AMK), gentamicin
(GEN), tobramycin (TOB), ciprofloxacin (CIP), colistin
(COL) and tigecycline (TGC).
Acinetobacter baumannii isolates were considered as
multi-drug resistant (MDRAB) if bacteria showed com-
bined resistance to ampicillin-sulbactam (SAM), piper-
acillin-tazobactam (TZP), antipseudomonal cephalosporins
(CAZ, FEP), fluoroquinolones (CIP), aminoglycosides
(AMK, GEN, TOB) and carbapenems (IPM, MEM).
Infection based on MDRAB-related infection was con-
firmed on the basis of case definitions of healthcare-
associated infections (Anonymous, 2012a).
Data were processed with statistical software WHONET
5.5.
RESULTS
In the time period from 2009 to 2013, prevalence of
MDRAB in Rîga East University Hospital Clinical Centre
Gaiïezers increased from 71 to 207 cases per year, followed
by a decrease to 113 cases in 2015 (Fig. 1). The maximum
number of cases was observed in 2013 when 217 isolates
were recorded.
Compared to the situation in other clinical centres of Rîga
East University Hospital — Biíernieki (BIK), Linezers
(LIN), Oncology Centre of Latvia (LOC), Latvian Centre of
Infectious Diseases (LIC), and Centre of Tuberculosis and
Lung Diseases (TBC), the decrease prevalence of MDRAB
in the clinical centre Gaiïezers has been most prominent
(Fig. 2).
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The proportion of bloodstream and CNS infections by
MDRAB was 15.85% or 78 cases (Table 1).
In 2013, there were 33 MDRAB isolates from blood and
cerebrospinal fluid indicating invasive infection while in
2014 this number decreased to 26 and further to 19 cases in
2015.
A decreasing tendency occurred between 2013 and 2015 in
cases of MDRAB infection (Fig. 3).
All patients with bloodstream infections and central nervous
system infections were treated with colistin, which was ad-
ministered via intravenous and intrathecal routes for pa-
tients with meningitis.
In patients with bloodstream infections and central nervous
system infections, resistance of Acinetobacter baumannii to
various antibiotics was reported in 2013 to occur in over
80% of cases (Table 2).
Fig. 1. Number of MDRAB isolates over years in the
Rîga East University Hospital Clinical Centre Gaiïezers.
Fig. 2. Number of MDRAB isolates in clinical centres of
Rîga East University Hospital. G, Gaiïezers; BIK,
Biíernieki; LIN, Linezers; LOC, Oncology Centre of
Latvia; LIC, Latvian Centre of Infectious Diseases; TBC,
Centre of Tuberculosis and Lung Diseases.
Fig. 3. Number of bloodstream infections and central ner-
vous system infections (INV) and other site infection or
colonisation (NON) MDRAB cases in the period
2013–2015.
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T a b l e 1











72 92.31% Central venous catheter related
sepsis in 46 patients (63.89%)
Meningitis 6 7.69% No meningitis cases in 2015
Total 78 100%
In REUH, colistin is mainly used to treat infections caused
by Acinetobacter baumannii and resistant strains reached
very high numbers in 2013.
In 2014, resistance of Acinetobacter baumannii to various
antibiotics was reported to be above 90% in most cases,
which was an alarming increase compared to the level in
previous years (Table 3).
Comparing data from 2013 and 2014, resistance of Acineto-
bacter baumannii increased to imipenem, ciprofloxacin and
colistin, while decreased slightly to amikacin.
Imipenem resistance in 2013 was observed in 87.9% (95%
CI = 70.9–96.1) isolates, while in 2014–92.3% (95% CI =
73.4–98.7), showing an increasing tendency. Also, resis-
tance to ciprofloxacin increased from 87.1% (95% CI =
69.2–95.8) in 2013 to 92.3% (95% CI = 73.4–98.7) in 2014.
Amikacin resistance decreased slightly from 80% (95% CI
= 60.9–91.6) in 2013 to 76.9% (95% CI = 55.9–90.2) in
2014.
Resistance to colistin increased from 0% (95% CI =
0.0–13.7) in 2013 to 4% (95% CI = 0.2–22.3) in 2014.
DISCUSSION
Our study indicated a relatively high prevalence of
MDRAB isolates in patients treated in the Rîga East Uni-
versity Hospital Clinical Centre Gaiïezers. The percentage
of patients infected with MDRAB that had combined resis-
tance to fluoroquinolones (CIP), aminoglycosides (GEN,
TOB) and carbapenems (IPM, MEM) in REUH was
76.9–92.3%.
Data of the European Centre of Disease Prevention and
Control (ECDC) on invasive Acinetobacter spp. number
and resistance in 2013 in the EU/EEA countries (Anony-
mous, 2014a) suggest that Latvia could be among worst
performing countries, along with Greece, Bulgaria, Croatia,
Italy, Spain, and Portugal.
There has been an endemic spread of MDRAB in the Rîga
East University Hospital.
This is both a clinical and public health problem that needs
to be addressed with full seriousness. Spread of MDRAB
not only substantially limits antimicrobial treatment op-
tions, but also creates difficulties for effective infection con-
trol in the hospital. Successful infection control measures,
identification and elimination of new MDRAB sources in
environment, review of the central venous catheter insertion
protocol and improvements in hand hygiene are crucial for
decreasing frequency of MDRAB spread in hospital envi-
ronment and serious invasive infections caused MDRAB.
The high resistance level will complicate the situation in the
future because of the need to use reserve antibiotics. The
appearance of Acinetobacter baumannii resistance to colis-
tin in 2014 is particularly alarming.
Apparently, contact isolation of patients is not sufficient to
stop spread of MDRAB in the hospital setting and airborne
infection isolation is necessary.
Among bloodstream infections, a large numbers of patients
received central venous catheter-related sepsis (63.89%).
This indicates a need to further review the central venous
catheter insertion procedure.
In order to reduce unnecessary use of antibiotics, it is very
important to clearly distinguish colonisation from invasive
infections.
It is very important to delay selection of pan-resistant
Acinetobacter baumannii and other resistant gram-negative
flora by controlling and mastering correct antibiotic use in
REUH as well as antibiotic stewardship and improving sur-
veillance networks.
CONCLUSIONS
Over the last two years (2014–2015), prevalence of
MDRAB infections has decreased considerably. Resistance
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T a b l e 2
RESISTANCE OF ACINETOBACTER BAUMANNII TO VARIOUS AN-
TIBIOTICS IN 2013
Antibiotic Abbreviation %R (% of
resistant)
%R 95%C.I.
Ampicillin/Sulbactam SAM 87.1 69.2–95.8
Piperacillin/Tazobactam TZP 87.9 70.9–96.1
Ceftazidime CAZ 87.1 69.2–95.8
Cefepime FEP 84.4 66.5–94.1
Imipenem IPM 87.9 70.9–96.1
Meropenem MEM 92.3 73.4–98.7
Amikacin AMK 80 60.9–91.6
Gentamicin GEN 77.4 58.4–89.7
Tobramycin TOB 78.1 59.5–90.0
Ciprofloxacin CIP 87.1 69.2–95.8
Colistin COL 0 0.0–13.7
T a b l e 3
RESISTANCE OF ACINETOBACTER BAUMANNII TO VARIOUS AN-
TIBIOTICS IN 2014
Antibiotic Abbreviation %R (% of
resistant)
%R 95%C.I.
Ampicillin/Sulbactam SAM 87.5 66.5–96.7
Piperacillin/Tazobactam TZP 91.7 71.6–98.6
Ceftazidime CAZ 92 72.5–98.6
Cefepime FEP 91.7 71.6–98.6
Imipenem IPM 92.3 73.4–98.7
Meropenem MEM 92 72.5–98.6
Amikacin AMK 76.9 55.9–90.2
Gentamicin GEN 80.8 60.0–93.7
Tobramycin TOB 76.9 55.9–90.2
Ciprofloxacin CIP 92.3 73.4–98.7
Colistin COL 4 0.2–22.3
of Acinetobacter baumannii is of concern in REUH. Resis-
tance increased to imipenem, ciprofloxacin and colistin,
while decreased slightly to amikacin from 2013 to 2014.
Systematic implementation of infection control measures
like identification and elimination of new MDRAB sources
in the environment, review of the central venous catheter in-
sertion protocol and improvements in hand hygiene are cru-
cial for decreasing frequency of MDRAB spread in the hos-
pital environment and invasive infections caused by
MDRAB.
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MULTIREZISTENTÂS ACINETOBACTER BAUMANNII IZPLATÎBAS MAZINÂÐANÂS RÎGAS AUSTRUMU KLÎNISKAJÂ
UNIVERSITÂTES SLIMNÎCÂ
Rîgas Austrumu klîniskajâ universitâtes slimnîcâ (RAKUS), kas ir lielâkâ stacionârâs aprûpes iestâde Latvijâ, pçdçjo gadu laikâ ir izteikta
tendence pieaugt inficçtîbai ar multirezistento Acinetobacter baumannii (MRAB) slimnîcâ. Acinetobacter baumannii ir gram-negatîvs,
strikti aerobs, neizvçlîgs, nefermentatîvs patogçns, kurð kâ patogçns tiek identificçts ar veselîbas aprûpi saistîtu infekciju gadîjumos: ar
veselîbas aprûpi saistîta pneimonija (îpaði ar mâkslîgo plauðu ventilâciju saistîta pneimonija), centrâlo asinsvadu katetru infekcijas, urînceïu
infekcijas, íirurìiskâs brûces infekcijas un cita veida brûces infekcijas. MRAB sagâdâ îpaðas raizes praksç, jo tâ izraisîto infekciju
ârstçðanai praktiski ir tikai viens antibakteriâls lîdzeklis — kolistîns. MRAB izplatîbas apmçra apzinâðanai tika apkopoti 2009.–2015. gadu
dati, bet jutîbas profilam — 2013.–2014. gadu dati. 2013. gadâ tika pârskatîti centrâlo venozo katetru ievietoðanas protokoli, veiktas roku
higiçnas intervences un meklçti MRAB avoti slimnîcas vidç. MRAB izplatîba RAKUS pieaug kopð 2009. gada, kad tika konstatçts 71
gadîjums, 2013. gadâ — 217 gadîjumi, bet 2014. gadâ — 172 gadîjumi un 2015. gadâ vairs tikai 113 gadîjumi. No asinîm un
lumbâlpunktâta izdalîto MRAB skaits: 2013. gadâ — 33 gadîjumi, 2014. gadâ — 26 gadîjumi, 2015. gadâ — 19. Imipençma rezistence
2013. gadâ — 87.9 % (95 % CI = 70.9–96.1), 2014. gadâ — 92.3 5 (95 % CI = 73.4–98.7); amikacîna rezistence 2013. gadâ — 80 % (95%
CI = 60.9–91.6), 2014. gadâ — 76.9 % (95% CI = 55.9–90.2), bet kolistîna rezistence 2013. gadâ — 0% (95 % CI = 0.0–13.7), 2014. gadâ
— 4% (95 % CI = 0.2–22.3). Salîdzinot RAKUS datus un Eiropas slimîbas profilakses centra uzraudzîbas datus par antimikrobiâlâs
rezistences uzraudzîbu Eiropas Savienîbâ/Eiropas Ekonomiskajâ Savienîbâ, secinâms, ka RAKUS ir endçmiska invazîvo MRAB izplatîba.
Konstatçts zems MRAB saistîtu asinsstraumes un CNS infekciju îpatsvars (15.16%). Asinsstraumes infekciju vidû augsts ar centrâlo
venozo katetru saistîtu sepses gadîjumu (62.26% no asinsstraumes infekcijâm). MRAB pacientu izolâcijâ nav pietiekoða kontakta tipa
izolâcija. Kopð 2013. gada vçrojama MRAB skaita mazinâðanâs, kas ir saistîta ar sekmîgu centrâlo venozo katetru ievietoðanas protokolu
ievieðanu, veiktajâm roku higiçnas intervencçm un jaunu MRAB avotu identifikâciju un to novçrðanu slimnîcas vidç.
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